Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT ID: NCT00681356

Last Updated: 2009-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing primary unilateral total knee arthroplasty

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Knee Arthroplasty (Replacement)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

4975 - 15 mg

Group Type EXPERIMENTAL

4975, 15 and 5 mg

Intervention Type DRUG

Direct instillation into the surgical site

2

Placebo

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

Direct instillation into the surgical site

3

4975 - truncated for Phase 3

Group Type EXPERIMENTAL

4975 - 5 mg

Intervention Type DRUG

Direct instillation into the surgical site

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

4975, 15 and 5 mg

Direct instillation into the surgical site

Intervention Type DRUG

Placebo Comparator

Direct instillation into the surgical site

Intervention Type DRUG

4975 - 5 mg

Direct instillation into the surgical site

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adlea

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, or III
* Planning to undergo primary unilateral Total Knee Arthroplasty (TKA)

Exclusion Criteria

* A body mass index (BMI) greater than 43
* Known bleeding disorder or is taking agents affecting coagulation preoperatively
* Use of medications or a medical condition that in the investigator's opinion could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments
* Diabetes mellitus with a known HbA1C\>9.5 or a history of prolonged uncontrolled diabetes
* Previous knee arthroplasty (partial or total) of the same knee
* Participated in another clinical trial within 30 days prior to the planned TKA surgery
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Anesiva, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anesiva, Inc,

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shaun Comfort, MD

Role: STUDY_DIRECTOR

Anesiva, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics, LLC

Birmingham, Alabama, United States

Site Status

Springhill Medical Center

Mobile, Alabama, United States

Site Status

Hellen Keller Hospital

Sheffield, Alabama, United States

Site Status

Visions Clinical Research/Tucson Medical Center

Tucson, Arizona, United States

Site Status

Glendale Adventist Medical Center - Lotus Clinical Research

Glendale, California, United States

Site Status

Physicians Clinical Research Corporation

Laguna Hills, California, United States

Site Status

Saddleback Memorial Medical Center/Accurate Clinical Trials

Laguna Hills, California, United States

Site Status

Webster Orthopeadic Medical Group

Oakland, California, United States

Site Status

UCSF-Mt. Zion Medical Center

San Francisco, California, United States

Site Status

Orthopedic Associates of Hartford

Hartford, Connecticut, United States

Site Status

Florida Hospital - Florida Research Associates, LLC

DeLand, Florida, United States

Site Status

University of Miami, Miller School of Medicine

Miami, Florida, United States

Site Status

Miami Institute for Medical Research

Miami, Florida, United States

Site Status

Southeastern Clinical Research Consultants

Orlando, Florida, United States

Site Status

Coastal Medical Research

Port Orange, Florida, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Ruxton Professional Center - Orthopaedic Associates

Towson, Maryland, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

William Beaumont Hospital

Troy, Michigan, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Sewickley Valley Hospital

Sewickley, Pennsylvania, United States

Site Status

Presbyterian Hospital of Dallas

Dallas, Texas, United States

Site Status

Memorial City Hospital - Memorial Hermann Healthcare System

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hartrick CT, Pestano C, Carlson N, Hartrick S. Capsaicin instillation for postoperative pain following total knee arthroplasty: a preliminary report of a randomized, double-blind, parallel-group, placebo-controlled, multicentre trial. Clin Drug Investig. 2011 Dec 1;31(12):877-82. doi: 10.1007/BF03256925.

Reference Type DERIVED
PMID: 21971213 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

114-01P

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.